Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2016; 37(02): 100-105
DOI: 10.4103/0971-5851.180134
ORIGINAL ARTICLE

Nonrhabdomyosarcomatous abdominopelvic sarcomas: Analysis of prognostic factors

Nida Iqbal
Department of Medical Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India
,
Nootan K Shukla
Department of Surgical Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India
,
S. V. S. Deo
Department of Surgical Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India
,
Sandeep Agarwala
Department of Pediatric Surgery, All India Institute of Medical Sciences, New Delhi, India
,
D Sharma
Department of Radiation Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India
,
Meher C Sharma
Department of Pathology, All India Institute of Medical Sciences, New Delhi, India
,
Sameer Bakhshi
Department of Medical Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
  PDF Download Permissions and Reprints

Abstract

Background: Data concerning treatment outcome and prognostic factors in sarcomas of abdomen and pelvis are sparse in literature.Methods and Results: Of 696 patients with nonrhabdomyosarcomatous soft tissue sarcoma registered at our center between June 2003 and December 2012, 112 (16%) patients of sarcomas arising from abdomen and pelvis were identified, of which 88 patients were analyzed for treatment outcome and prognostic factors. The median age was 40 years (range: 1–78 years) with a male: female ratio of 0.7:1. Twenty-one (24%) patients were metastatic at baseline. The most common tumor sites were retroperitoneum in 70% patients and abdominal wall in 18% patients. Leiomyosarcoma was the most common histological subtype in 36% patients followed by liposarcoma in 17% patients. Thirty-five (40%) patients had Grade III tumors. Forty-six (52%) patients underwent surgical resection. At a median follow-up of 43 months (range: 2–94 months), the 5-year event-free survival (EFS) and overall survival (OS) were 35% and 42%, with a median of 22 months and 43 months, respectively. Multivariate analysis identified male gender (P - 0.03, hazard ratio [HR] - 0.46, 95% confidence interval [CI] - 0.23–0.92), baseline metastatic disease (P - 0.01, HR - 2.98, 95% CI - 1.27–6.98) and Grade III tumors (P - 0.02, HR - 1.84, 95% CI - 1.08–3.13) as factors associated with poor EFS, whereas baseline metastatic disease (P < 0.001, HR - 5.45, 95% CI - 2.31–12.87) and unresectability (P - 0.01, HR - 2.72, 95% CI - 1.27–5.83) were associated with poor OS. Conclusion: This is a single-institutional study of patients with abdominopelvic sarcomas where gender was identified as a new factor affecting survival apart from baseline presentation, histologic grade, and surgical resection.

Keywords

Abdomen - gender - pelvis - prognostic factors - sarcoma


Publication History

Article published online:
12 July 2021

© 2016. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Fletcher CD, Bridge JA, Hogendoorn PC, Mertens F. World Health Organization Classification of Tumours of Soft Tissue and Bone. 4th ed. Lyon: IARC Press; 2013.
  • 2 DeVita VT Jr, Hellman S, Rosenberg SA. Cancer: Principles and Practice of Oncology. 6th ed. Philadelphia: Lippincott Williams and Wilkins; 2001. p. 1841-91.
  • 3 Lewis JJ, Leung D, Woodruff JM, Brennan MF. Retroperitoneal soft-tissue sarcoma: Analysis of 500 patients treated and followed at a single institution. Ann Surg 1998;228:355-65.
  • 4 Jaques DP, Coit DG, Hajdu SI, Brennan MF. Management of primary and recurrent soft-tissue sarcoma of the retroperitoneum. Ann Surg 1990;212:51-9.
  • 5 Liles JS, Tzeng CW, Short JJ, Kulesza P, Heslin MJ. Retroperitoneal and intra-abdominal sarcoma. Curr Probl Surg 2009;46:445-503.
  • 6 Catton CN, O'Sullivan B, Kotwall C, Cummings B, Hao Y, Fornasier V. Outcome and prognosis in retroperitoneal soft tissue sarcoma. Int J Radiat Oncol Biol Phys 1994;29:1005-10.
  • 7 Wang TY, Lo SS, Su CH, Wu CW, Lui WW. Surgical management of primary retroperitoneal sarcoma. Zhonghua Yi Xue Za Zhi (Taipei) 1996;58:177-82.
  • 8 Cheifetz R, Catton CN, Kandel R, O'Sullivan B, Couture J, Swallow CJ. Recent progress in the management of retroperitoneal sarcoma. Sarcoma 2001;5:17-26.
  • 9 Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
  • 10 Van Dam PA, Lowe PG, McKenzie-Gray B, Shepherd JH. Retroperitoneal soft tissue sarcomas. Obstet Gynecol Surv 1990;45:670-82.
  • 11 Sondak VK, Economou JS, Eilber FR. Soft tissue sarcomas of the extremity and retroperitoneum: Advances in management. Adv Surg 1991;24:333-59.
  • 12 Shiu MH, Weinstein L, Hajdu SI, Brennan MF. Malignant soft-tissue tumors of the anterior abdominal wall. Am J Surg 1989;158:446-51.
  • 13 Berchuck A, Rubin SC, Hoskins WJ, Saigo PE, Pierce VK, Lewis JL Jr. Treatment of uterine leiomyosarcoma. Obstet Gynecol 1988;71:845-50.
  • 14 Stojadinovic A, Hoos A, Karpoff HM, Leung DH, Antonescu CR, Brennan MF, et al. Soft tissue tumors of the abdominal wall: Analysis of disease patterns and treatment. Arch Surg 2001;136:70-9.
  • 15 Pirayesh A, Chee Y, Helliwell TR, Hershman MJ, Leinster SJ, Fordham MV, et al. The management of retroperitoneal soft tissue sarcoma: A single institution experience with a review of the literature. Eur J Surg Oncol 2001;27:491-7.
  • 16 Bevilacqua RG, Rogatko A, Hajdu SI, Brennan MF. Prognostic factors in primary retroperitoneal soft-tissue sarcomas. Arch Surg 1991;126:328-34.
  • 17 Kilkenny JW 3rd, Bland KI, Copeland EM 3rd. Retroperitoneal sarcoma: The University of Florida experience. J Am Coll Surg 1996;182:329-39.
  • 18 Sorbye SW, Kilvaer TK, Valkov A, Donnem T, Smeland E, Al-Shibli K, et al. Prognostic impact of Skp2, ER and PGR in male and female patients with soft tissue sarcomas. BMC Clin Pathol 2013;13:9.
  • 19 Valkov A, Sorbye S, Kilvaer TK, Donnem T, Smeland E, Bremnes RM, et al. Estrogen receptor and progesterone receptor are prognostic factors in soft tissue sarcomas. Int J Oncol 2011;38:1031-40.